With more than a year lag between the launch of its first two startups, the venture capital- and big pharma VC-backed biotechnology incubator Cydan Development Inc. is on track to reach its goal of founding five orphan drug-focused firms in four years, including its second venture, Imara Inc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?